EW
PR
EV
I

Benchmarking European
Investigator Payments

Info@ISRreports.com 	
	

	

©2014 Industry Standard Research

www...
act with confidence

Report Overview
This report provides an analysis of Europe’s clinical trial compensation for investig...
act with confidence

What you will learn in this report:
•	
•	
•	
•	

Average compensation investigators receive per subje...
act with confidence

Table of Contents
For table of contents and additional sample pages, please download the full preview...
act with confidence

Sample Page: Report Introduction
Introduction

act with confidence

Introduction
One way to to ISR’s ...
act with confidence

Sample Page
Introduction

act with confidence

Average Compensation per Patient by Therapeutic Area a...
act with confidence

Sample Page
For table of contents and additional sample pages, please download the full preview from ...
act with confidence

Ordering Information
For pricing and ordering information, please visit our website:
http://bit.ly/1d...
The ISR Difference

act with confidence

Custom-quality syndicated market research
www.ISRreports.com

ISR's Reports

vs.
...
Upcoming SlideShare
Loading in …5
×

Benchmarking European Investigator Payments

529 views

Published on

This report provides an analysis of Europe’s clinical trial compensation for investigator payments across 18 therapeutic areas, 5 compound types, and the 4 phases of development. It provides pharmaceutical, biotech, and service providers an opportunity to gain a better understanding of what drives investigator payments so they can benchmark their payment levels and better plan for study costs.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
529
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Benchmarking European Investigator Payments

  1. 1. EW PR EV I Benchmarking European Investigator Payments Info@ISRreports.com ©2014 Industry Standard Research www.ISRreports.com
  2. 2. act with confidence Report Overview This report provides an analysis of Europe’s clinical trial compensation for investigator payments across 18 therapeutic areas, 5 compound types, and the 4 phases of development. It provides pharmaceutical, biotech, and service providers an opportunity to gain a better understanding of what drives investigator payments so they can benchmark their payment levels and better plan for study costs. Methodologies: Germany = 40 respondents France = 39 respondents Eastern Europe = 20 respondents UK = 43 respondents ISR conducted 142 online quantitative surveys with respondents who • • • Currently work at a research site … are located in Western or Eastern Europe … have responsibility for investigator payments 312 Charts and Graphs 104 Pages Q1, 2014 Publication Date Report Structure: 1. Executive Summary 2. Benchmarking Investigator Fees • • • • Phase comparison by specialty/therapeutic area Compound type compensation by specialty/therapeutic area Region/ country comparison by phase Region/ country comparison by compound type 3. Investigator Payment Dynamics • Understand what motivates investigators to participate in clinical trials and where compensation falls in the rankings. ISR presents respondents with clinical trial scenarios and asks how investigator fee requirements would need to change as inclusion/exclusion criteria, visit frequency, and difficulty of test schedule are varied. 4. Profiled Specialty/Therapeutic Area 5. Site and Respondent Demographics Therapeutic Areas Evaluated: • Analgesic/Pain Management • Cardiovascular • CNS • Dermatology • Gastrointestinal • • • • • Hematology Infectious Diseases Internal Medicine Metabolic Diseases Musculoskeletal/ Arthritis • • • • • Oncology Ophthalmology Orthopedics Pediatric Respiratory/Allergy/ Pulmonology • Urology • Vaccines • Women’s Health Compound Types Included: • Biologic • Biosimilar • Me-too • Generic • Novel www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 2
  3. 3. act with confidence What you will learn in this report: • • • • Average compensation investigators receive per subject for each therapy area by phase and compound orientation/ type How study characteristics (length and complexity) change fee levels What motivates investigators to participate in a trial Therapeutic area profiles How you can use this report: • • • Optimize your investigator payments across therapeutic areas, phases of development, compound type under investigation, and geography Establish and better negotiate investigator payments Use “trial complexity” and “length of study” as variables to create more accurate budget projections and lower costs Valuable for: • • • • • • Project Management Clinical Operations Outsourcing Trial Budgeting Feasibility CRO Proposals Up next: Full table of contents and sample pages www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 3
  4. 4. act with confidence Table of Contents For table of contents and additional sample pages, please download the full preview from our website: http://bit.ly/1dpPqGd www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 4
  5. 5. act with confidence Sample Page: Report Introduction Introduction act with confidence Introduction One way to to ISR’s the Russian clinical trial and pharmaceutical environment is Welcome think aboutsecond Investigator Payments report to think of the highlightingcountry as a publically tradedpresentation, youcompany� If a comEurope’s clinical trial pharmaceutical would find you were compensation. In this leafing through a prospectus or an investor report, ISR wanted fundamentals, historicunderstanding of what pany with strong macro to gain a better growth, inconsistent performance, and some regulatory uncertainty� In short, that has many of the same characterdrives investigator payments so Russiasponsors and CROs can istics as a mid-stage pharmaceutical company� you take a portfolio theory benchmark their paymentlikely want to And, if some portion of your assets levels and better plan for study costs. approach to investing, you would invest in Russia� Why? Determinants of investigator payments come in many forms ↑ Macroeconomics: Russia is the world’s 10th largest economy such as therapeutic area, compound orientation, trial complexity, ↑ patient needs. Is there the World Trade Organization (WTO) in 2012 andInternational recognition: Joineda one-size-fits-all formula that ↑ be applied sheet: Russia has ~$240B trade to produce the reserves canPositive balanceuniformly across studiessurplus from fossil fuelmost ↑ Focus: compensation plan? Perhaps not, but medicines this effective Putin announced $3�9B plan aimed at having 90% ofby using to be locally produced by 2020 array of compensation averages provided by site personnel ↑ by understanding their non-monetary motivations for trial andReimbursement structure: Medicines Insurance System (Aug 2012) is to be in place by 2020 that will include a participation, ISR believes a tiered rate of reimbursement, depending on sponsor or CRO can recruit and the nature of the illness, and improve access to medications retain high quality sites without breaking the budget. ↑ Growth: Russian pharmaceutical market has been growing 17% annually since 2005 ↑ Untapped potential: Many patients are treatment naïve, offering opportunities for clinical trial patient recruitment ↓ Uncertainty: Regulatory environment and customs practices are unstable and unpredictable ↓ Difficult: In 2012 the World Bank ranked Russia 122nd on their list of economies by ease of doing business, 21 spots below China ↓ Skills: Finding highly qualified healthcare professionals can be difficult ↓ Protection: IP protection is concerning www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile 7 www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 5
  6. 6. act with confidence Sample Page Introduction act with confidence Average Compensation per Patient by Therapeutic Area and Phase Only therapeutic areas with 4 or more responses in a phase are included in the following sections. In terms of investigator highest compensation for Phase ranked as II-IV, Internal Internal Medicine had the payment fees, only oncology I. For Phase one of the top three most below average compensation. Medicine receivedexpensive therapeutic area across phase II, III, and IV of development. Oncology received the highest compensation for Phase II and the third highest compensation for Phase III and Phase IV. Oncology received below average compensation for Phase I. Phase I Phase II Phase Pediatric did not IV Phase Pediatric received the highest compensation for Phase III compounds. III receive enough responses to be reported in the other phases. Highest Oncology Analgesic / Pain Compensation Management received the highest compensation for Phase IV. In all ($7,676) other phases, analgesic / pain management fell below average for compensation. Second Highest Ophthalmology received the second highest average compensation for Phase I and Data available in full report Phase III. Ophthalmology did not receive enough responses for Phase II or Phase IV. Third Highest Average Phase I Phase II Phase III Phase IV Highest Compensation Internal Medicine ($12,125) Oncology ($7,676) Pediatric ($11,200) Analgesic / Pain Management ($5,000) Second Highest Ophthalmology ($7,750) Third Highest Vaccines ($6,750) Musculoskeletal/ Arthritis ($5,071) Oncology ($7,136) Oncology ($2,591) Average $5,529 $4,159 $4,604 $2,441 Metabolic Ophthalmology Diseases ($5,333) ($7,250) Hematology ($4,000) ©2014 Industry Standard Research www.ISRreports.com ©2014 | Benchmarking European Investigator Payments 15 www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 6
  7. 7. act with confidence Sample Page For table of contents and additional sample pages, please download the full preview from our website: http://bit.ly/1dpPqGd www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 7
  8. 8. act with confidence Ordering Information For pricing and ordering information, please visit our website: http://bit.ly/1dpPqGd About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 8
  9. 9. The ISR Difference act with confidence Custom-quality syndicated market research www.ISRreports.com ISR's Reports vs. The Common Syndicated Report How confident are you? Research methods Mostly primary research; always appropriate for the topic vs. vs. One size fits all; usually publically available data Data Collection ISR's proprietary data collection tools and channels support fast, high quality data collection vs. Struggle to recruit the right targets and enough of them Respondents Sophisticated screening ensures genuine decision-makers vs. Undisclosed methodologies and respondent demographics Sample Sizes Robust sample sizes that instill confidence vs. Often insufficient industry representation that leaves you defending results Analysts Decades of experience means more insights that are immediately usable vs. vs. Junior analysts capable of reporting numbers www.ISRreports.com ©2013©2014 | Preview of: Benchmarking European Investigator Functions www.ISRreports.com | Preview of: Benchmarking the Pharma Industry’s HEOR Payments 9

×